Clintrax Global, Inc.

clintraxglobal.com

Clintrax Global provides Investigator Agreement negotiation and payment services for Clinical Research Organizations and Pharmaceutical companies worldwide. We specialize in short contract cycle times with comprehensive legal review. We have the ability to service large, global investigator contract FSP work in addition to one-off CRO study rescue.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

HOVIONE EXPANDS DRUG PRODUCT OFFERING WITH A NEW MANUFACTURING LINE DEDICATED TO CONTINUOUS TABLETING

Hovione | September 07, 2022

news image

Hovione, the leader in spray drying and particle engineering, announced that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal. In addition, to support Hovione's commitment to providing access and services for continuous tableting, Hovione has further strengthened its capabilities by establishing a highly experienced multi-disciplinary global team in continuous table...

Read More

Pharma Tech

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Iktos | December 09, 2021

news image

Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Under the agreement, Iktos’ de novo generative design software Makya™ will be used by Hengrui scientists to ...

Read More

Research

PFIZER AND BIONTECH NAB COVID-19 VACCINE AUTHORIZATION FROM U.K. FOR FIRST-EVER MARKETED MRNA SHOT

Pfizer | December 03, 2020

news image

The two organizations' BNT162b2 has become the primary COVID-19 immunization permitted in the Western world as medication controllers in the U.K. given out a crisis use approval on Wednesday, in front of choices by the U.S. also, Europe, which are normal soon. For the more extensive immunization world, the Medicines and Healthcare items Regulatory Agency's choice methods the world currently has the principal mRNA shot approved for far reaching use, opening up a fresh out o...

Read More

Pharma Tech

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

news image

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More
news image

Business Insights

HOVIONE EXPANDS DRUG PRODUCT OFFERING WITH A NEW MANUFACTURING LINE DEDICATED TO CONTINUOUS TABLETING

Hovione | September 07, 2022

Hovione, the leader in spray drying and particle engineering, announced that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal. In addition, to support Hovione's commitment to providing access and services for continuous tableting, Hovione has further strengthened its capabilities by establishing a highly experienced multi-disciplinary global team in continuous table...

Read More
news image

Pharma Tech

IKTOS ANNOUNCES DEPLOYMENT OF THEIR AI FOR DRUG DESIGN SOFTWARE MAKYA™ BY JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Iktos | December 09, 2021

Iktos, a company specialized in Artificial Intelligence for new drug design today announced recent collaboration agreement in AI for new drug design with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a leading global pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. Under the agreement, Iktos’ de novo generative design software Makya™ will be used by Hengrui scientists to ...

Read More
news image

Research

PFIZER AND BIONTECH NAB COVID-19 VACCINE AUTHORIZATION FROM U.K. FOR FIRST-EVER MARKETED MRNA SHOT

Pfizer | December 03, 2020

The two organizations' BNT162b2 has become the primary COVID-19 immunization permitted in the Western world as medication controllers in the U.K. given out a crisis use approval on Wednesday, in front of choices by the U.S. also, Europe, which are normal soon. For the more extensive immunization world, the Medicines and Healthcare items Regulatory Agency's choice methods the world currently has the principal mRNA shot approved for far reaching use, opening up a fresh out o...

Read More
news image

Pharma Tech

MERCK DRIVES NEW INNOVATION & ADDS CAPACITY TO ADVANCE NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) THERAPIES

Merck | October 29, 2021

Merck, a leading science and technology company, today announced that its Life Science business sector has launched new technology and expanded capacity to advance ADC therapies. These initiatives underscore Merck's continued investment in novel modalities and support the company's efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. "ADCs have experienced remarkable growth, with commerci...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us